A BOUTIQUE CDMO DEDICATED TO SMALL QUANTITIES APIs

About us

DIVERCHIM is a Small Molecule Drug Substance CDMO which focuses on developing and manufacturing high added-value Active Ingredients:

Drug candidates APIs
APIs for Orphan Drugs and Rare Diseases
Radiopharmaceutical Precursors
Niche specialty chemicals

More than 20 years serving the development of New Chemical Entities,

from a CRO to a CDMO

Memberships

Our values

Describe your image

1/5

Memberships

DIVERCHIM is highly committed in running its business with high level of ethical considerations and developing manufacturing processes that are environmentally responsible.

Safety

Gender Equality

45%

55%

EcoVadis certification

Yasmine

Bencheikh

HSE Manager

Claire

Brayer

Office Manager

Sarah

Delecrin

QA and Regulatory

Affairs Director

Bruno

Dudot

Head of Large

Scale Production

Benoît

Folléas

CSO, Head of Project

Management

Fabien

Lajus

Head of QC Lab. And Analytical Development

Jessica

Le Manac'h

Head of HR and Accounting

François

Macarez

CEO

Cédric

Ngoulou

Head of Purchasing

Solutions

Comprehensive offering, from Preclinical stage to Commercial Supply, dedicated to the

development and manufacturing of:

Small molecule APIs (including RSM and advanced intermediates)
Radiopharmaceutical precursors
GMP excipients and Linkers

NON-NATURAL AMINO-ACIDS – PEPTIDES – POLYMERS – NANO-LIPIDS – HYDROGELS – OLIGONUCLEOTIDES – NUCLEOSIDES

Services

Development phase

Additional services include:

Lyophilization and Solid aliquotating of Radiopharmaceutical precursors
Reference standards
Standalone analytics

• Team of 6 lead by QA Director with 20-year experience in QA

• ICHQ7 based quality system

• GMP certification of the site since 2015

• Last audit: July-22

• Site registered by FDA since 2021

• ”FDA-ready” site (2 Mock inspections conducted in 2024 to prepare PAI)

•Project management Director, member of Executive Committee team

•Nomination of a dedicated PM at the start-up of each project

•Management of activities (Route scouting, Developments, Validation, Stability studies, Production) handled by a PM

•Project team includes experts of all services to ensure a smooth execution to comply with customer’s request

•Stage gate Process:

State-of-the-art 3000 m² facility built in 2013

From g-scale GMP to dozens of kilo

Our facility is strategically located just 20 kilometers north of Paris, near the Roissy-Charles de Gaulle airport

This prime location provides us with exceptional connectivity, allowing for efficient logistics and accessibility to key international hubs

Capabilities

Special Features

10-years experience in the development and manufacturing of GMP Precursors and excipients
30 projects handled since 2016
10 active customers – from emerging biotechs to larger players in the nuclear medicine

Track Record

Extensive in-house expertise in Solid Phase Synthesis for the manufacturing of Peptides
Glass dedicated reactors

GMP Peptide Synthesis

2 qualified equipment

Bulk Lyophilization

Solid aliquoting: Manual and Automatic (Auto-sampler) filling
Liquid aliquoting: 2 equipment (2R – 50R vials)

Gentisic Acid (CAS RN: 490-79-9)
DTPA (CAS RN: 67-43-6)
Ammonium acetate (CAS RN: 631-61-8)
EDDA(CAS RN: 67-43-6)
Sodium ascorbate (CAS RN: 134-03-2)

Aliquoting in Iso 5 environment

GMP Excipients and Buffers

Launch (2024) of PickASO project with the support of BPI France to develop an ASO for an innovative therapy to activate autophagy

Commercial partner : THERANEXUS

Scientific partner : INSERM

Antisense therapy is a form of treatment that uses antisense oligonucleotides (ASOs) to target messenger RNA (mRNA). ASOs are capable of altering mRNA expression through a variety of mechanisms